Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04406389 · ClinicalTrials.gov registry record · Phase 4
Anticoagulation in Critically Ill Patients With COVID-19 (The IMPACT Trial)
A Phase 4 study, sponsored by Weill Medical College of Cornell University.
- Terminated
- Registry status
- Phase 4
- Development phase
- 14
- Enrollment target
NCT04406389: Clinical Trial Phase 4 study, sponsored by Weill Medical College of Cornell University.
NCT04406389 is a Phase 4 study that was terminated before completion, run by Weill Medical College of Cornell University. The registered enrollment target is 14 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04406389, a Phase 4 study, was terminated before completion, sponsored by Weill Medical College of Cornell University.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 14 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if therapeutic dose anticoagulation (experimental group) improves 30-day mortality in participants with COVID-19 compared to those patients receiving the intermediate dose prophylaxis (control group). Following screening, subjects will be randomized 1:1 to intermediate dose prophylaxis or therapeutic dose anticoagulation treatment arms.Treatment will continue for 28 days, followed by a 6 month follow-up period.
Primary Outcome
Comparison of number of COVID-19 positive patients who have died within 30 days of starting treatment on each treatment arm
Interventions
- DRUG Argatroban
- DRUG Enoxaparin sodium
- DRUG Unfractionated heparin
- DRUG Fondapariniux
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2020-10-13 |
| Est. Completion | 2022-04-21 |
| Phase | Phase 4 |
Why NCT04406389 stopped before completion
NCT04406389 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 4 interventions - of which Argatroban is the first listed.
NCT04406389 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04406389 about?
NCT04406389 is a clinical study titled "Anticoagulation in Critically Ill Patients With COVID-19 (The IMPACT Trial)". The purpose of this study is to determine if therapeutic dose anticoagulation (experimental group) improves 30-day mortality in participants with COVID-19 compared to those patients receiving the intermediate dose prophylaxis (control group). Following screening, subjects will be randomized 1:1 to i...
What is the current status of trial NCT04406389?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 14 participants. The study started on 2020-10-13. Estimated completion is 2022-04-21.
What interventions are being tested in trial NCT04406389?
The interventions under investigation include: Argatroban (DRUG), Enoxaparin sodium (DRUG), Unfractionated heparin (DRUG), Fondapariniux (DRUG).
Who is sponsoring clinical trial NCT04406389?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04406389's enrollment target sits among peer trials
14 1901st of 2000 higher than 91 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy